In the Journals

Power morcellation technique increases mortality risk for women with occult uterine sarcoma

October 11, 2019
Uncontained power morcellation appeared associated with increased risk for mortality among women with occult uterine sarcoma, according to study…

Orthopedics Today Grand Rounds

A 75-year-old woman with constitutional symptoms, precipitous functional decline

Orthopedics Today, September 2019
Bayard C. Carlson, MD; Douglas W. Bartels, MD; Joshua D. Johnson, MD; Peter S. Rose, MD
A 75-year-old woman with a medical history significant for obesity, diabetes mellitus type 2 and coronary artery disease presented with a 6-month…

FDA News

T-cell therapy receives FDA’s orphan drug status for soft tissue sarcoma

September 9, 2019
The FDA has granted orphan drug designation to ADP-A2M4, an investigational specific peptide-enhanced affinity receptor T-cell therapy, for the…

Meeting News

IASLC: All physicians should screen patients with cancer for tobacco use

September 7, 2019
BARCELONA — The International Association for the Study of Lung Cancer, or IASLC, today issued a declaration at its World Conference on Lung…

FDA News

FDA approves pexidartinib, first therapy for tenosynovial giant cell tumor

August 2, 2019
The FDA announced today approved pexidartinib for the treatment of adults with symptomatic tenosynovial giant cell tumor that is linked to functional…

FDA News

FDA grants priority review to tazemetostat for epithelioid sarcoma

July 25, 2019
The FDA granted priority review to tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma who are not…

In the JournalsPerspective

Neurotoxicity Affects Nearly Half of Patients Receiving CAR T-cell Therapy

Cell Therapy Next, July 2019
New data revealed that 48% of patients who received chimeric antigen receptor T-cell therapy for cancer treatment experienced neurological toxicity…

Meeting News

Enrollment on genomically matched clinical trials improves sarcoma outcomes

July 17, 2019
CHICAGO — Patients with various subtypes of pretreated, metastatic sarcoma showed improved response rates and survival when treated on…

In the Journals

Race/ethnicity, socioeconomic status associated with increased risk for death among young cancer survivors

July 17, 2019
Non-Latino white adolescents and young adults who are cancer survivors have a lower risk for subsequent death compared with survivors of other races…

Meeting NewsVideo

VIDEO: Intensity Therapeutics’ intratumoral formulation active in highly refractory cancers

June 26, 2019
CHICAGO — Lewis H. Bender, MS, MA, MBA, founder, president and CEO of Intensity Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting…


ASCO Annual Meeting: I got plenary of nothing!

HemOnc Today, June 25, 2019
Derek Raghavan, MD, PhD
Here we are, back from another bigger, better, more extreme ASCO Annual Meeting. Every year, about this time, I return from what is billed as the…

In the Journals

Chronic pain inhibits daily life for 1 in 6 cancer survivors

June 20, 2019
About one in three cancer survivors, representing nearly 5.4 million people in the United States, reported experiencing chronic pain, with one in six…

Meeting NewsVideo

VIDEO: Studies in lung cancer, sarcoma highlight Eli Lilly presentations at ASCO

June 20, 2019
CHICAGO — Maura Dickler, MD, vice president of late-phase oncology development at Eli Lilly, spoke with HemOnc Today about key data presented…

FDA News

FDA grants fast track designation to TRQ-1501 T-cell therapy for solid tumors, lymphoma

June 18, 2019
The FDA granted fast track designation to TRQ-1501, a deep-primed IL-15 T-cell immunotherapy for the treatment of relapsed or refractory solid tumors…

Meeting NewsPerspective

MIW815 plus spartalizumab safe, active among certain patients with advanced breast cancer, melanoma

June 17, 2019
CHICAGO — Patients with anti-PD-1-naive triple-negative breast cancer and PD-1-relapsed or refractory melanoma demonstrated antitumor benefit…

Meeting NewsVideo

Adaptimmune executive: T-cell therapy induces response in synovial sarcoma

June 10, 2019
CHICAGO — Rafael Amado, MD, president of research and development for Adaptimmune, spoke with HemOnc Today at ASCO Annual Meeting about…

Meeting NewsPerspective

Phase 3 trial fails to confirm OS benefit of olaratumab in advanced soft tissue sarcoma

June 7, 2019
CHICAGO — The randomized phase 3 ANNOUNCE trial failed to confirm the OS benefit of adding olaratumab to standard doxorubicin for patients with…

Meeting News

Pembrolizumab demonstrates acceptable safety among patients with cancer and HIV

June 6, 2019
CHICAGO — Pembrolizumab exhibited an acceptable safety profile among patients with cancer and HIV who had more than 100 CD4 cells/µL and…

Meeting News

Atul Gawande, MD, MPH: When treating patients, ‘our core goal is to enable their goals’

June 1, 2019
CHICAGO — When treating

Meeting NewsPerspective

Addition of temozolomide to vincristine, irinotecan may improve outcomes in relapsed rhabdomyosarcoma

May 31, 2019
CHICAGO — The addition of temozolomide to vincristine and irinotecan may improve outcomes among children and adults with relapsed or refractory…